Eli Lilly shares jump nearly 6% after USFDA approves weight-loss pill
Eli Lilly shares jumped nearly 6% on Wednesday after the U.S. Food and Drug Administration approved its weight-loss pill, Foundayo, marking a significant milestone in the drugmaker’s efforts to expand its foothold in the lucrative obesity market. The approval will likely intensify the rivalry between Lilly and Novo Nordisk, as they battle for dominance in…
